Vertex Pharmaceuticals | VRTX - Market Capitalization


Vertex Pharmaceuticals reported $125.1B in Market Capitalization this August of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 435.86B 8.73B Aug/2026
Acadia Pharmaceuticals USD 4.53B 199M Aug/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amgen USD 209.65B 14.21B Aug/2026
Arrowhead Research USD 11.15B 2.37B Aug/2026
Biogen USD 31.9B 5B Jun/2026
BioMarin Pharmaceutical USD 11.58B 712M Aug/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Gilead Sciences USD 168.68B 11.82B Aug/2026
Incyte USD 26.84B 4.19B Aug/2026
Insmed USD 35.3B 1.82B Mar/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
J&J USD 611.36B 32.21B Jun/2026
Merck USD 324.18B 6.81B Aug/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 240.59B 67.17B Jun/2026
Pfizer USD 143.89B 5.44B Aug/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Roche Holding CHF 270B 3.66B Jun/2026
Sanofi EUR 91.15B 9.12B Jun/2026
Sarepta Therapeutics USD 1.54B 747M Aug/2026
Ultragenyx Pharmaceutical USD 2.12B 1.16B Aug/2026
United Therapeutics USD 24.41B 780M Aug/2026
Vertex Pharmaceuticals USD 121.59B 4.48B Aug/2026